ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California.
"We are excited to share these presentations with the scientific community, demonstrating the breadth and versatility of our Axiomer RNA editing technology," said Gerard Platenburg, Chief Scientific Officer of ProQR. "The data we will present at ASGCT and TIDES further support our vision of building a differentiated and diversified pipeline and advancing RNA editing therapies that could offer transformative benefits for patients."
These presentations will highlight the Company's proprietary Axiomer RNA editing platform and pipeline programs. Details of ProQR's presentations are as follows:
American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
May 13-17, 2025 | New Orleans, Louisiana, USA
Oral Presentation
Title: ADAR-Mediated RNA Editing of SLC10A1(NTCP) as a Therapeutic Approach to Reduce Liver Bile Acid Re-Uptake in Cholestatic Diseases (abstract 333)
Presenter: Gerard Platenburg, Chief Scientific Officer
Date/Time: May 16, 2025, 4:15 PM CT
Session: Oligonucleotide Therapeutics II
Poster Presentations
Title: ADAR-Mediated RNA Editing-Based Correction of PNPLA3 I148M Functionality to Address Hepatic Steatosis (abstract 1654)
Presenter: Gerard Platenburg, Chief Scientific Officer
Date/Time: May 15, 2025, 5:30-7:00 PM CT
Poster Number: AMA1324
Title: ADAR-Mediated RNA Editing of Premature Termination Codon Results in Functional Correction in MECP2 for Rett Syndrome (abstract 1645)
Presenter: Gerard Platenburg, Chief Scientific Officer
Date/Time: May 15, 2025, 5:30-7:00 PM CT
Poster Number: AMA1427
TIDES USA: Oligonucleotide and Peptide Therapeutics Conference
May 19-22, 2025 | San Diego, California, USA
Podium Presentation
Title: Advancing Axiomer ADAR RNA Editing Platform - Editing oligonucleotides optimization for therapeutic use
Presenter: Peter A. Beal, PhD, Chief ADAR Scientist
Date/Time: May 22, 2025, 2:00 PM PST
Session/Track: Genome Editing Technology and Applications
Following the conferences, presentation materials will be made available in the Publications and Presentations section of the ProQR website at www.proqr.com.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer 'Editing Oligonucleotides', or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements for ProQR
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'continue,' "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our presentations at these conferences, our business, preclinical model data, our initial pipeline targets and the upcoming strategic priorities and milestones related thereto, our Axiomer™ RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides and our ability to expand preclinical in vivo and in vitro data, the timing, progress and results of our preclinical studies and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates, as well as the timing of our clinical development. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference, our business, technology, strategy, our Axiomer platform, including the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228skiely@proqr.comorInvestor contact:Peter KelleherLifeSci AdvisorsT: +1 617 430 7579 pkelleher@lifesciadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
A Bull Case for Apple: Is It a Sleeping Giant?
Apple's product concentration is both a risk and an opportunity. The tech company is exploring new categories with spatial computing and artificial intelligence. New product categories strengthen the flywheel effect of Apple's cohesive ecosystem of hardware, software, and services. 10 stocks we like better than Apple › Apple (NASDAQ: AAPL) has underwhelmed investors this year. As of this writing, shares are down about 19% year to date. That compares with a gain of about 4% for the S&P 500 during the same time frame. The stock's underperformance has been driven by the company's disappointing growth. Apple's revenue in the first half of the year, for instance, grew just 4.4% year over year. With the tech company's total annual revenue hovering at around the $400 million level since 2022, there are some concerns that the iPhone maker may be nearing its maximum global sales potential. But before you count Apple out, consider the following unique bull case for the stock. It might change your mind. Apple's concentrated product line is primarily viewed as a risk for the company. For example, the fact that the iPhone accounts for about half of Apple's total sales means that any weakness in the key category will weigh heavily on the overall business. Adding to Apple's concentration risk, just three product categories -- iPhone, Mac, and iPad -- account for about two-thirds of the company's total annual sales. In addition, if you include the company's wearables, home, and accessories segment, primarily consisting of sales of Apple Watch and AirPods, in an assessment of Apple's product category concentration, just five product lines represent about three-fourths of total sales. The remaining sales come from Apple's services segment, which is diversified across a range of services, has a higher profit margin, and is more predictable than hardware sales. But if you flip the script, there's another way to look at this product concentration. Apple's powerful business model and its global and loyal customer base enable it to generate about $300 billion worth of product sales annually from just four product categories. Therefore, considering how much a single product category can move the needle for the company, a single successful new product would be a likely major tailwind for the company. Indeed, this is exactly what Apple did with AirPods and Apple Watch. Thanks to the launch of these iconic and wildly popular devices, starting with the Apple Watch in 2015 and the AirPods in 2016, the company's wearables, home, and accessories segment now represents more than 9% of total sales. And, looking further back, the company did the same thing with the iPad when it was launched in 2010. Today, the iPad represents 7% of total sales. All of this to say, the company's sales growth rates could materially accelerate if Apple sees success in a new product category. Strengthening this investment thesis for Apple even more, the analysis here arguably understates the impact of new product categories on the overall business. The reason is that every new product has a flywheel effect on other areas of the business, too. For instance, when a customer buys his or her first Apple Watch or iPad, it's likely to increase overall engagement with the Apple ecosystem, leading to higher services revenue, greater loyalty, and ultimately higher lifetime customer value. Today, Apple is already venturing into new product categories that could morph into major revenue streams in the future. The most notable one is the company's foray into spatial computing with Vision Pro. Launched just last year, these new goggles mark a new era of spatial computing, Apple CEO Tim Cook said just before deliveries of the new device started. While the new product is still considered a niche item that most customers pass on, it shows that the company is willing to explore new areas that could become the next iPad, Apple Watch, or AirPods for the company. In addition, investors shouldn't rule out Vision Pro specifically as a potential future catalyst. While it's not a major driver for the company today, future iterations of the device could lead to a tipping point in customer utility. With all of this said, Apple stock's price-to-earnings ratio of about 31 already seems to price in a return to higher growth rates at some point in the future. But this thesis at least helps strengthen the case for holding shares through this lull in growth. Still, the risks are significant. For instance, it's possible Apple's sales growth rates will never return to robust high-single-digit rates. An unfortunate outcome like this could be caused by weakness in one of the company's major product categories or simply a failure to gain traction in any new categories. But even with these risks in mind, the overall risk-reward profile seems attractive enough to hold onto shares. The fact that the company has been able to grow as much as it has over the past decade with just a handful of product categories suggests that Apple will likely find another new category over the next decade to help the company return to strong growth again. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple. The Motley Fool has a disclosure policy. A Bull Case for Apple: Is It a Sleeping Giant? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
A Rookie Investor Says, 'I Have Made Multiple Years Of My Salary In One Week.' He Admits, 'I Do Not Believe I Can Go Back To Normal Life'
A novice investor claims he made over $200,000 in just one week trading options, saying the experience has made it hard to return to everyday life. On Reddit's r/wallstreetbets, he shared a screenshot of his Robinhood (NASDAQ:HOOD) account showing a balance of $210,000 and a nearly 4,000% return in the past month. 'I have made multiple years of my salary in one week,' he wrote. 'No matter how this ends, it's been a great ride.' Don't Miss: Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share. Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. The investor revealed he began trading just three months ago with $55,000. He confirmed that his gains came from selling SPDR S&P 500 ETF Trust (NYSE:SPY) call and put credit spreads, often using 0DTE—zero days to expiration— contracts. His screenshots showed multiple positions closed on June 20 with returns ranging from 36% to 72%. 0DTEs are trades that expire the same day they're made. They're popular with short-term traders looking to profit from quick market moves within hours. 'It made me understand that normal people are selling their time for money, and the rich are buying their time with money,' he commented later. He admitted that the rush of winning large trades changed how he thinks about work and life altogether. 'I do not believe I can go back to normal life.' Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — Now Raising at $3/Share Dozens of users who had experienced similar wins warned that it rarely lasts. 'I did something similar back in 2020,' one wrote. 'I felt like a genius and started drinking my own Kool-Aid. Then I lost half of what I made and it's been a five-year slog to get back.' Another said: 'Be careful. Going back to a 9-to-5 is really, really f***ing hard.' The OP responded with appreciation: 'Thank you for the advice, especially for someone who has tread this path before me. I will consider this, brother.' While many were urging caution, a few users encouraged him to keep trading, saying things like, 'Race ain't over till you have $2.5 million after tax,' and 'Don't quit, keep going until you get a million.'But the majority were clearly worried. Some pointed out that the trading strategy was sustainable only with discipline and a healthy exit plan. 'Don't lie to yourself that you're some genius of investment, you GAMBLED and lucked out,' one said. 'Take the money, put it into some non-gambling investment and retire early.' The top comment, with over 15,000 upvotes, was straightforward: 'Bro, stop and restart with 10k, get your life situated. You'll never regret it.' By the end of the thread, he said he intended to withdraw at least $100,000 and was weighing his options. 'I believe making $200,000 in one month is significant and advances my timetable for retirement,' he wrote. For now, he seems to be sitting at the intersection of life-changing luck and community-driven wisdom. Read Next: Can you guess how many retire with a $5,000,000 nest egg? The percentage may shock 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article A Rookie Investor Says, 'I Have Made Multiple Years Of My Salary In One Week.' He Admits, 'I Do Not Believe I Can Go Back To Normal Life' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
an hour ago
- Yahoo
US–China deal fuels stock gains, Nike soars, Nvidia nears $4T
Yahoo Finance's John Hyland takes a closer look at some of the top stories of the trading day on Yahoo Finance's Market Minute. Renewed optimism about trade deals sends US stocks (^DJI, ^GSPC, ^IXIC) higher. Nike (NKE) stock soars after reporting earnings that signal successful turnaround efforts from CEO Elliott Hill. Nvidia's (NVDA) market capitalization could hit $4 trillion after the chipmaker's stock hits several record highs. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's Market Minute. US stocks are pushing higher today and looking to close out at all-time highs as the S&P 500 and Nasdaq trade in record territory. The stock rally gaining momentum after the US and China confirmed their trade deals and as economic data eased concerns about the impact of tariffs. Plus, Nike shares surging today as the company's turnaround gains traction. The retailer is forecasting a smaller than expected drop in revenue for the current quarter. Before today's gains, the stock had lost a third of its value over the past 12 months. And Nvidia shares pushing higher today after closing out at a new record high in Thursday's trade. The company is on a path to be valued at $4 trillion. It would be the first company to ever reach that valuation. And that's your Yahoo! Finance Market Minute. For more on what's trending on Yahoo! Finance, scan the QR code below to track the best and worst performing stocks of the trading session. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
